Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+ Breast Cancer With Early Recurrence.

Anticancer research - 1 Feb 2020

Yamashita Hiroko, Ishida Naoko, Hatanaka Yutaka, Hagio Kanako, Oshino Tomohiro, Takeshita Takashi, Kanno-Okada Hiromi, Shimizu A I, Hatanaka Kanako C, Matsuno Yoshihiro

Abstract excerpt

BACKGROUND/AIM: In estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, standard chemotherapies as well as adjuvant endocrine therapy might not be enough for prevention of early relapse. MATERIALS AND METHODS: We focused on ER-positive, HER2 immunohistochemistry (IHC) 0 or 1+ breast cancer, and retrospectively examined HER2 gene amplification and TP53 mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunohistochemistry

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 32014905
DOI: 10.21873/anticanres.13994

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+ Breast Cancer With Early Recurrence.PMID 32014905Read ↗

Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer.Semantic proximity Read ↗

Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative breast cancer: An ad-hoc analysis of the JBCRG-C06 Safari studySemantic proximity Read ↗

Favorable Locoregional Control in Clinically Node- Negative Hormone-receptor Positive Breast Cancer With Low 21-gene Recurrence Scores: a Single Institutional Study With 10-year Follow-upSemantic proximity Read ↗

Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer.Semantic proximity Read ↗

Age related influence of triple receptor status on metastatic breast cancer post relapse survival.Semantic proximity Read ↗

Gene Expression Profiles for Recurrence of Lymph Node-positive Primary Breast Cancer in Women Over 40 Years of AgeSemantic proximity Read ↗

Moderate Immunohistochemical Expression of HER-2 (2+) Without <i>HER-2</i> Gene Amplification Is a Negative Prognostic Factor in Early Breast CancerSemantic proximity Read ↗

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.Semantic proximity Read ↗

Amplified Loci on Chromosomes 8 and 17 Predict Early Relapse in ER-Positive Breast CancersSemantic proximity Read ↗

Ki67 Assessment by qRT-PCR in OncotypeDx ® Breast Recurrent Score®: Low Correlation With IHC Assessment of ki67 and Prognostic Impact of ki67 RNA Level of Expression.Semantic proximity Read ↗

Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation.Semantic proximity Read ↗

Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.